- Integration
- Processes the submission's supported DICOM CT, MR, CR, US, NM, PT, and XA inputs; local routing, archive, and acceptance behavior are not established.
FDA source Exact FDA submission Checked 2026-09-04
- Deployment and data flow
- Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-04
Deployment details for the exact cleared configuration are not established in the public FDA decision material.
- Security and privacy
- Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04
Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.
- Training and support
- Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
FDA source Exact FDA submission Checked 2026-09-04
- Monitoring and change control
- Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-04
Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.
Release and scope verification
Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K254189 before acceptance.
exact submission · checked 2026-09-04 Later product-family features are not evidence that this cleared release includes them.
Interoperability acceptance
Processes the submission's supported DICOM CT, MR, CR, US, NM, PT, and XA inputs; local routing, archive, and acceptance behavior are not established.
exact submission · checked 2026-09-04 Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Clinical acceptance
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA material does not make this a mammography primary-diagnosis claim; exact modality, configuration, and local clinical use must remain within the labeled scope.
exact submission · checked 2026-09-04 Define stop-use, escalation, rollback, and revalidation triggers before production use.
Economic evaluation
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04 No exact-product price was found in the evidence set; productivity or value claims require local evidence.
Lifecycle monitoring
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.
exact submission · checked 2026-09-04 Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.